Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone density at 12 months in postmenopausal women with osteoporosis. We assessed the effects of annual infusions of zoledronic acid on fracture risk during a 3-year period. METHODS: In this double-blind, placebo-controlled trial, 3889 patients (mean age, 73 years) were randomly assigned to receive a single 15-minute infusion of zoledronic acid (5 mg) and 3876 were assigned to receive placebo at baseline, at 12 months, and at 24 months; the patients were followed until 36 months. Primary end points were new vertebral fracture (in patients not taking concomitant osteoporosis medications) and hip fracture (in all patients). Secondary end points included bone mineral density, bone turnover markers, and safety outcomes. RESULTS: Treatment with zoledronic acid reduced the risk of morphometric vertebral fracture by 70% during a 3-year period, as compared with placebo (3.3% in the zoledronic-acid group vs. 10.9% in the placebo group; relative risk, 0.30; 95% confidence interval [CI], 0.24 to 0.38) and reduced the risk of hip fracture by 41% (1.4% in the zoledronic-acid group vs. 2.5% in the placebo group; hazard ratio, 0.59; 95% CI, 0.42 to 0.83). Nonvertebral fractures, clinical fractures, and clinical vertebral fractures were reduced by 25%, 33%, and 77%, respectively (P<0.001 for all comparisons). Zoledronic acid was also associated with a significant improvement in bone mineral density and bone metabolism markers. Adverse events, including change in renal function, were similar in the two study groups. However, serious atrial fibrillation occurred more frequently in the zoledronic acid group (in 50 vs. 20 patients, P<0.001). CONCLUSIONS: A once-yearly infusion of zoledronic acid during a 3-year period significantly reduced the risk of vertebral, hip, and other fractures. (ClinicalTrials.gov number, NCT00049829.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Zoledronic acid reduces the incidence of vertebral fractures by 70 % (with significant reduction at 1 year), hip fractures by 41 %, and nonvertebral fractures by 25 % over 3 years in patients with osteoporosis defined by prevalent vertebral fractures and osteoporosis by BMD of the hip [66].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
In the citing paper
“There is abundant evidence that the elevated risk of fracture in patients with osteoporosis by BMD is reduced with pharmacotherapy [52, 57, 59–70].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
In the citing paper
“Zoledronic acid reduces the incidence of vertebral fractures by 70 % (with significant reduction at 1 year), hip fractures by 41 %, and nonvertebral fractures by 25 % over 3 years in patients with osteoporosis defined by prevalent vertebral fractures and osteoporosis by BMD of the hip [66].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
In the citing paper
“Zoledronic acid reduces the incidence of vertebral fractures by 70 % (with significant reduction at 1 year), hip fractures by 41 %, and nonvertebral fractures by 25 % over 3 years in patients with osteoporosis defined by prevalent vertebral fractures and osteoporosis by BMD of the hip [66].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationVertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Cummings, S. R. (1998) · JAMA · doi:10.1001/jama.280.24.2077 · Cited by 2,277
Self-citationOsteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J., & Engroff, S. L. (2004) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2004.02.004 · Cited by 2,057
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Self-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Self-citationSystematic Review: Bisphosphonates and Osteonecrosis of the Jaws
Woo, S.-B., Hellstein, J. W., & Kalmar, J. R. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00009 · Cited by 1,252
Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040325 · Cited by 1,229
Self-citation
Cited by
Items 201–300 of 1,004
Fracture Outcomes Related to Persistence and Compliance With Oral Bisphosphonates
Gallagher, A. M., Rietbrock, S., Olson, M. S., & van Staa, T. P. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080510 · Cited by 140
New targets for intervention in the treatment of postmenopausal osteoporosis
Lewiecki, E. M. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.130 · Cited by 159
Grbic, J. T., Landesberg, R., Lin, S., Mesenbrink, P. G., Reid, I. R., Leung, P., Casas, N., Recknor, C. P., Hua, Y., Delmas, P. D., et al. (2008) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2008.0017 · Cited by 150
“Thorough analysis of bone fractures in the HORIZON-PFT did not reveal that zoledronic acid had any adverse effects on fracture healing.(28) The antiangiogeneic effect of bisphosphonates has been reported in in vitro and animal models.”
BackgroundMethodResultInfluentialSelf-citationOsteoporosis and Its Complications
Varacallo, M. A., & Fox, E. J. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.03.007 · Cited by 151
Bisphosphonate Use and Prevalence of Valvular and Vascular Calcification in Women
Elmariah, S., Delaney, J. A. C., O'Brien, K. D., Budoff, M. J., Vogel-Claussen, J., Fuster, V., Kronmal, R. A., & Halperin, J. L. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.05.050 · Cited by 136
Eriksen, E. F., Lyles, K. W., Colon-Emeric, C. S., Pieper, C. F., Magaziner, J. S., Adachi, J. D., Hyldstrup, L., Recknor, C. P., Nordsletten, L., Lavecchia, C., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090209 · Cited by 144
“At each study visit, patients were asked whether they had (1) sustained a new nonvertebral fracture or (2) had new or worsening back pain and spine radiographs obtained in routine clinical care.”
BackgroundSelf-citationKarsdal, M. A., Henriksen, K., Leeming, D. J., Mitchell, P., Duffin, K., Barascuk, N., Klickstein, L., Aggarwal, P., Nemirovskiy, O., Byrjalsen, I., et al. (2009) · Biomarkers · doi:10.1080/13547500902777608 · Cited by 135
“As a result, CTX-I is being used in a large number of studies (Black et al. 2007, McClung et al. 2006, Black et al. 2006, Ravn et al. 1999a, 2000, 2003, Tanko et al. 2004, Chesnut et al. 2000) as an indicator of bone resorption and as one component in a fracture-risk prediction models.”
MethodBisphosphonates and Risk of Cardiovascular Events: A Meta-Analysis
Kim, D. H., Rogers, J. R., Fulchino, L. A., Kim, C. A., Solomon, D. H., & Kim, S. C. (2015) · PLOS ONE · doi:10.1371/journal.pone.0122646 · Cited by 134
“Moreover, a possible increase in atrial fibrillation associated with bisphosphonates[23,24] may counteract the potential benefits on atherosclerotic CV disease.”
BackgroundMethodInfluentialSchwartz, A. V., Schafer, A. L., Grey, A., Vittinghoff, E., Palermo, L., Lui, L.-Y. L., Wallace, R. B., Cummings, S. R., Black, D. M., Bauer, D. C., et al. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1865 · Cited by 134
“In HORIZON, 7736 postmenopausal women aged 65 to 89 years were stratified into two groups based on current use of other osteoporosis medications and were randomized within the two strata to receive a once-yearly infusion (5mg) of zoledronic acid (ZOL) or placebo for up to 3 years.((19)) All women also received oral da…”
BackgroundMethodSelf-citationBoonen, S., Black, D. M., Colón‐Emeric, C. S., Eastell, R., Magaziner, J. S., Eriksen, E. F., Mesenbrink, P., Haentjens, P., & Lyles, K. W. (2010) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2009.02673.x · Cited by 134
“A once-yearly intravenous infusion of zoledronic acid (ZOL) 5 mg is a more-attractive therapeutic option in the management of osteoporosis than daily, weekly, or even monthly regimens of oral bisphosphonates.(25) Moreover, the use of intravenous ZOL 5 mg in preventing bone loss and reducing the risk of fractures is we…”
BackgroundMethodResultSelf-citationBisphosphonates for postmenopausal osteoporosis
Eastell, R., Walsh, J., Watts, N. B., & Siris, E. S. (2011) · Bone · doi:10.1016/j.bone.2011.02.011 · Cited by 147
“A recent abstract presented at the ASBMR 2010 [30] meeting reported a comparison of the effects of 6 years of annual 5 mg infusions followed by 3 years of placebo (Z3P3) versus 6 annual infusions of zoledronic acid (Z6) in an extension of the Horizon-PFT trial [31].”
Self-citationFactors Associated with Osteonecrosis of the Jaw among Bisphosphonate Users
Hess, L. M., Jeter, J., Benham-Hutchins, M. M., & Alberts, D. S. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.01.047 · Cited by 152
Jacques, R. M., Boonen, S., Cosman, F., Reid, I. R., Bauer, D. C., Black, D. M., & Eastell, R. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1644 · Cited by 129
“In the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly–Pivotal Fracture Trial (HORIZON-PFT),((7)) zoledronic acid reduced the risk of vertebral fractures by 70% (p< 0.”
BackgroundMethodSelf-citationCosman, F., Cauley, J. A., Eastell, R., Boonen, S., Palermo, L., Reid, I. R., Cummings, S. R., & Black, D. M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1971 · Cited by 129
“MorphVertFx were determined by central radiologic review, using a combination of quantitative morphometry and semi quantitative assessment (1).”
BackgroundMethodSelf-citationAnagnostis, P., Paschou, S. A., Mintziori, G., Ceausu, I., Depypere, H., Lambrinoudaki, I., Mueck, A., Pérez-López, F. R., Rees, M., Senturk, L. M., et al. (2017) · Maturitas · doi:10.1016/j.maturitas.2017.04.008 · Cited by 129
Osteoporosis: the current status of mesenchymal stem cell-based therapy
Phetfong, J., Sanvoranart, T., Nartprayut, K., Nimsanor, N., Seenprachawong, K., Prachayasittikul, V., & Supokawej, A. (2016) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-016-0013-1 · Cited by 136
“risedronate [108], and zoledronate [109].”
Eastell, R., Nagase, S., Ohyama, M., Small, M., Sawyer, J., Boonen, S., Spector, T., Kuwayama, T., & Deacon, S. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.341 · Cited by 126
“In the HORIZON-PFT and FREEDOM trials, zoledronic acid and denosumab reduced nonvertebral fracture risk by 25% and 20%, respectively.((3,4)) Furthermore, there is concern that by decreasing bone turnover for many years, there may be complications such as atypical fractures of the femur.”
MethodSelf-citationCosman, F., Krege, J. H., Looker, A. C., Schousboe, J. T., Fan, B., Sarafrazi, N., Shepherd, J., Krohn, K., Steiger, P., Wilson, K. E., et al. (2017) · Osteoporosis International · doi:10.1007/s00198-017-3948-9 · Cited by 136
Self-citationSambrook, P. N., Cameron, I. D., Chen, J. S., MARCH, L. M., Simpson, J. M., Cumming, R. G., & Seibel, M. J. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1444-6 · Cited by 127
“Zoledronic acid is associated with a higher risk of acute phase reaction than other bisphosphonates, which theoretically could influence an elderly person"s underlying immune system status [15].”
Cardiovascular effects of calcium supplementation
Reid, I. R., Bolland, M. J., Avenell, A., & Grey, A. B. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1599-9 · Cited by 127
“0% in the phase 3 trial, which co-administered calcium and vitamin D [35].”
BackgroundResultSelf-citationRenal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women
Boonen, S., Sellmeyer, D. E., Lippuner, K., Orlov-Morozov, A., Abrams, K. B., Mesenbrink, P. G., Eriksen, E. F., & Miller, P. D. (2008) · Kidney International · doi:10.1038/ki.2008.193 · Cited by 127
Self-citationThe Incidence of Osteonecrosis of the Jaw in Patients Receiving 5 Milligrams of Zoledronic Acid
Grbic, J. T., Black, D. M., Lyles, K. W., Reid, D. M., ORWOLL, E. S., McClung, M. R., Bucci-Rechtweg, C. M., & Su, G. (2010) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2010.0082 · Cited by 126
Self-citationBisphosphonates: how do they work?
Papapoulos, S. E. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.07.001 · Cited by 162
Anastasilakis, A. D., Pοlyzos, S. A., & Makras, P. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0056 · Cited by 131
Do we need to adjudicate major clinical events?
Granger, C. B., Vogel, V., Cummings, S. R., Held, P., Fiedorek, F., Lawrence, M., Neal, B., Reidies, H., Santarelli, L., Schroyer, R., et al. (2008) · Clinical Trials · doi:10.1177/1740774507087972 · Cited by 124
“There are recent examples of where safety outcomes (with clear definitions and accurate determination) have been of major importance to overall trial interpretation, such as myocardial infarction in COX-2 inhibitor trials [14] and heart failure in thiazoladinedione trials [15], and the occurrence of atrial fibrillatio…”
BackgroundSelf-citationBisphosphonates and Atrial Fibrillation: Systematic Review and Meta-Analysis
Loke, Y. K., Jeevanantham, V., & Singh, S. (2009) · Drug Safety · doi:10.2165/00002018-200932030-00004 · Cited by 128
Molecular-Based Treatment Strategies for Osteoporosis: A Literature Review
Ukon, Y., Makino, T., Kodama, J., Tsukazaki, H., Tateiwa, D., Yoshikawa, H., & Kaito, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102557 · Cited by 128
“, risedronate, ibandronate, and zoledronate [97].”
BackgroundDeardorff, W. J., Cenzer, I. S., Nguyen, B., & Lee, S. J. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.6745 · Cited by 146
Delmas, P. D., Munoz, F., Black, D. M., Cosman, F., Boonen, S., Watts, N. B., Kendler, D., Eriksen, E. F., Mesenbrink, P. G., & Eastell, R. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090310 · Cited by 120
“(27–31) This paper presents further details about changes in BTMs with treatment with zoledronic acid and a posthoc analysis of the relationship between BTMs and the occurrence of incident fractures from the randomized, doubleblind, placebo-controlled Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yea…”
BackgroundMethodInfluentialSelf-citationUse of Osteoporosis Medications after Hospitalization for Hip Fracture: A Cross-national Study
Kim, S. C., Kim, M.-S., Sanfélix-Gimeno, G., Song, H. J., Liu, J., Hurtado, I., Peiró, S., Lee, J., Choi, N.-K., Park, B.-J., et al. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.01.014 · Cited by 120
Masud, T., Binkley, N., Boonen, S., & Hannan, M. T. (2011) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2011.05.010 · Cited by 133
“Pivotal randomised controlled trials of anti-osteoporotic therapies including alendronate (36,37), risedronate (38), zoledronate (39), denosumab (40) and strontium ranelate (post hoc) (41) show that the risk of hip fractures can be”
BackgroundSelf-citationBone Loss in the HIV-Infected Patient: Evidence, Clinical Implications, and Treatment Strategies
Harris, V. W., & Brown, T. T. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis199 · Cited by 134
“fractures by 25%–50% in non-HIV-infected patients [45, 46].”
BackgroundInfluentialBone Mineral Density After Transitioning From Denosumab to Alendronate
Kendler, D., Chines, A., Clark, P., Ebeling, P. R., McClung, M., Rhee, Y., Huang, S., & Stad, R. K. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz095 · Cited by 119
KEMMLER, W. K., Bebenek, M., Kohl, M., & von Stengel, S. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3165-3 · Cited by 148
“With respect to clinical overall fractures, zoledronate, that may actually be the most potent bisphosphonate [25], decreases fracture rate by 33 % [26] which is comparable with the anti-fracture efficacy of 32 and 35 % reported for denosumab [27] and teriparatide [28].”
ResultDoes osteocytic SOST suppression mediate PTH bone anabolism?
Krämer, I., Keller, H., Leupin, O., & Kneissel, M. (2010) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2009.12.002 · Cited by 128
Coleman, R. E., Woodward, E., Brown, J. E., Cameron, D., Bell, R., Dodwell, D. J., Keane, M., Gil, M., Davies, C., Burkinshaw, R., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1429-y · Cited by 120
Pharmacological treatment of osteoporosis in the oldest old
Vandenbroucke, A.-M., Luyten, F., Flamaing, J., & Gielen, E. (2017) · Clinical Interventions in Aging · doi:10.2147/cia.s131023 · Cited by 118
“The Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly – Pivotal Fracture Trial (HORIZON-PFT) has shown that zoledronic acid is an effective treatment in postmenopausal osteoporotic women (mean age =73 years), with, after 3 years, a significant reduction in the risk of vertebral, hip, and nonverteb…”
Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis
Belaya, Z. E., Belova, K. Y., Biryukova, E. V., Dedov, I. I., Dzeranova, L. K., Drapkina, O. M., Dreval', A. V., Dubovitskaya, Т. A., Dudinskaya, Е. N., Ershova, O. B., et al. (2021) · Osteoporosis and Bone Diseases · doi:10.14341/osteo12930 · Cited by 160
Underdiagnoses and Undertreatment of Osteoporosis: The Battle to Be Won
Miller, P. D. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3156 · Cited by 127
Romosozumab and antiresorptive treatment: the importance of treatment sequence
Cosman, F., Kendler, D. L., Langdahl, B. L., Leder, B. Z., Lewiecki, E. M., Miyauchi, A., Rojeski, M., McDermott, M., Oates, M. K., Milmont, C. E., et al. (2022) · Osteoporosis International · doi:10.1007/s00198-021-06174-0 · Cited by 120
Self-citationDifferences between bisphosphonates in binding affinities for hydroxyapatite
Lawson, M. A., Xia, Z., Barnett, B. L., Triffitt, J. T., Phipps, R. J., Dunford, J. E., Locklin, R. M., Ebetino, F. H., & Russell, R. G. G. (2009) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.31500 · Cited by 117
Renal safety in patients treated with bisphosphonates for osteoporosis: A review
Miller, P. D., Jamal, S. A., Evenepoel, P., Eastell, R., & Boonen, S. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2058 · Cited by 116
“These data demonstrated that three annual infusions of zoledronic acid have no significant effect on eGFR((37)) and that any effect on SCr—even in patients who have received six annual zoledronic acid infusions—is transient.”
BackgroundMethodInfluentialSelf-citationAntifracture Efficacy of Currently Available Therapies for Postmenopausal Osteoporosis
Reginster, J. (2010) · Drugs · doi:10.2165/11587570-000000000-00000 · Cited by 125
“Zoledronic acid HORIZON([40]) 2853/2822 73 62-64 0.”
BackgroundInfluentialHormone replacement therapy – where are we now?
Langer, R. D., Hodis, H. N., Løbo, R. A., & Allison, M. (2021) · Climacteric · doi:10.1080/13697137.2020.1851183 · Cited by 139
McClung, M., Miller, P., Recknor, C., Mesenbrink, P., Bucci-Rechtweg, C., & Benhamou, C.-L. (2009) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3181bdce0a · Cited by 117
Self-citationPfeifer, M. A., Kohlwey, L., Begerow, B., & Minne, H. W. (2011) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/phm.0b013e31821f6df3 · Cited by 129
Eastell, R., Black, D. M., Boonen, S., Adami, S., Felsenberg, D., Lippuner, K., Cummings, S. R., Delmas, P. D., Palermo, L., Mesenbrink, P., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2765 · Cited by 116
Self-citationFRAX® assessment of osteoporotic fracture probability in Switzerland
Lippuner, K., Johansson, H., Kanis, J. A., & Rizzoli, R. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0975-1 · Cited by 129
“However, in the subgroup post hoc analyses performed in all these studies, there was no evidence in favour of differences in efficacy related to the presence or absence of these clinical risk factors [36–40].”
MethodGeusens, P., Marin, F., Kendler, D. L., Russo, L. A., Zerbini, C. A., Minisola, S., Body, J. J., Lespessailles, E., Greenspan, S. L., Bagur, A., et al. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3384 · Cited by 116
“Clinical fractures were analyzed as secondary fracture endpoints in the zoledronic acid and abaloparatide phase 3 trials,((22,26)) but they were not reported in the subgroup analyses.”
Self-citationDelmas, P. D. (2008) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2008.02.002 · Cited by 129
Self-citationDrug induced osteonecrosis of the jaw
Hamadeh, I. S., Ngwa, B. A., & Gong, Y. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.04.007 · Cited by 173
“Findings from randomized clinical studies [14–18] designed to evaluate the clinical efficacy of bisphosphonates in patients with osteoporosis demonstrated that their use resulted in about a 40–50% reduction in the risk of spine fractures and a 25% reduction in the risk of hip fractures accompanied by about a 5–8% incr…”
MethodLorentzon, M., Branco, J., Brandi, M. L., Bruyère, O., Chapurlat, R. D., Cooper, C. C., Cortet, B., Díez‐Pérez, A., Ferrari, S., Gáspárik, A. I., et al. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01063-9 · Cited by 132
The 2024 UK clinical guideline for the prevention and treatment of osteoporosis
Gregson, C. L., Armstrong, D., Avgerinou, C., Bowden, J., Cooper, C. C., Douglas, L., Edwards, J., Gittoes, N. J. L., Harvey, N. C., Kanis, J. A., et al. (2025) · Archives of Osteoporosis · doi:10.1007/s11657-025-01588-3 · Cited by 157
“Pre-existing hypocalcaemia must be investigated and, where due to vitamin D deficiency, treated with vitamin D (e.g., 100,000 to 300,000 IU orally as a loading dose in divided doses) before zoledronate treatment is initiated.”
Atrial fibrillation in fracture patients treated with oral bisphosphonates
Abrahamsen, B., Eiken, P., & Brixen, K. (2009) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02065.x · Cited by 117
Atypical Fractures as a Potential Complication of Long-term Bisphosphonate Therapy
Sellmeyer, D. E. (2010) · JAMA · doi:10.1001/jama.2010.1360 · Cited by 119
Self-citationGrey, A. B., Bolland, M. J., Horne, A. M., Wattie, D. J., House, M. E., Gamble, G. D., & Reid, I. R. (2012) · Bone · doi:10.1016/j.bone.2012.03.016 · Cited by 117
“The intravenous bisphosphonate, zoledronate, reduces fracture risk when administered annually [5,6], and its less frequent dosing may improve adherence to therapy during long-term treatment.”
BackgroundSelf-citationRadiographic methods for evaluating osteoporotic vertebral fractures
Grados, F., Fechtenbaum, J., Flipon, E., Kolta, S., Roux, C., & Fardellone, P. (2009) · Joint Bone Spine · doi:10.1016/j.jbspin.2008.07.017 · Cited by 124
“Name of the study Medication Criteria used to diagnose incident vertebral fractures FIT [54] Alendronate Morphometric radiography (at least 20% and 4 mm decrease in at least one vertebral height versus baseline) confirmed by SQA VERT [55] Risedronate Morphometric radiography (at least 15% decrease in at least one vert…”
ResultOsteoporosis in Older Persons: Old and New Players
Zanker, J., & Duque, G. (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15716 · Cited by 112
Bertoldo, F., Pancheri, S., Zenari, S., Boldini, S., Giovanazzi, B., Zanatta, M., Valenti, M. T., Carbonare, L. D., & Cascio, V. L. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090819 · Cited by 141
“The baseline levels of 25(OH)D in the randomized, controlled trials evaluating zoledronic acid efficacy in osteoporosis are not mentioned.((16,19))”
BackgroundResultInfluentialAn Update on Dual-Energy X-Ray Absorptiometry
Blake, G. M., & Fogelman, I. (2009) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2009.08.001 · Cited by 153
Bone Health in Adult Cancer Survivorship
Lustberg, M. B., Reinbolt, R. E., & Shapiro, C. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.2097 · Cited by 110
Díez‐Pérez, A., Marín, F., Eriksen, E. F., Kendler, D. L., Krege, J. H., & Delgado‐Rodríguez, M. (2018) · Bone · doi:10.1016/j.bone.2018.09.020 · Cited by 116
Self-citationThe clinical role of dual energy X-ray absorptiometry
Blake, G. M., & Fogelman, I. (2009) · European Journal of Radiology · doi:10.1016/j.ejrad.2008.04.062 · Cited by 131
Effect of Zoledronate on Oral Wound Healing in Rats
Yamashita, J., Koi, K., Yang, D.-Y., & McCauley, L. K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1614 · Cited by 125
Treatment of osteoporosis in men
Kaufman, J., Reginster, J.-Y., Boonen, S., Brandi, M. L., Cooper, C. C., Dere, W. H., Devogelaer, J.-P., Díez‐Pérez, A., Kanis, J. А., McCloskey, E. V., et al. (2012) · Bone · doi:10.1016/j.bone.2012.11.018 · Cited by 117
“Overall, thefindings showed changes in surrogate outcomes (bone density and bone turnover) in line with those reported in pivotal trials of postmenopausal women [66].”
Self-citationGrey, A., Bolland, M. J., Wattie, D., Horne, A., Gamble, G., & Reid, I. R. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2241 · Cited by 110
“(1) in an osteoporotic population, it is of interest to compare the findings of these studies.”
BackgroundResultSelf-citationA Meta-Analysis of Osteoporotic Fracture Risk with Medication Nonadherence
Ross, S. D., Samuels, E. R., Gairy, K., Iqbal, S. U., Badamgarav, E., & Siris, E. S. (2011) · Value in Health · doi:10.1016/j.jval.2010.11.010 · Cited by 122
“[7] Black DM, Delmas PD, Eastell R, et al.”
BackgroundSaito, T., Sterbenz, J. M., Malay, S., Zhong, L., MacEachern, M., & Chung, K. C. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4175-0 · Cited by 118
Osteoporosis Management in the Era of COVID-19
Yu, E. W.-Y., Tsourdi, E. A., Clarke, B. L., Bauer, D. C., & Drake, M. T. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4049 · Cited by 110
“However, the absolute risk of inducing clinically significant hypocalcemia after treatment with either zoledronic acid((8)) or denosumab((9)) is very low in the absence of significant renal insufficiency.”
BackgroundMatsumoto, T., Hagino, H., Shiraki, M., Fukunaga, M., Nakano, T., Takaoka, K., Morii, H., Ohashi, Y., & Nakamura, T. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0816-7 · Cited by 115
“Minodronate exhibits very similar antiresorptive potency to zoledronic acid in pre-clinical studies [7], and intermittent oral administration of ibandronate [15] as well as yearly intravenous administration of zoledronic acid [16] demonstrated potent anti-fracture efficacy.”
BackgroundHigano, C. S. (2008) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0995 · Cited by 113
Bisphosphonates for the treatment of osteoporosis: insights for clinicians
Lewiecki, E. M. (2010) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622310374783 · Cited by 122
Body, J. J., Bergmann, P., Boonen, S., Boutsen, Y., Devogelaer, J.-P., Goemaere, S., Reginster, J., Rozenberg, S., & Kaufman, J. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0439-4 · Cited by 113
“The observed cases were consistent with established risk factors like local infection and the condition resolved with antibiotic therapy [78].”
BackgroundSelf-citationA Coordinator Program in Post-Fracture Osteoporosis Management Improves Outcomes and Saves Costs
Sander, B., Elliot-Gibson, V., Beaton, D. E., Bogoch, E. R., & Maetzel, A. (2008) · The Journal of Bone & Joint Surgery · doi:10.2106/jbjs.g.00980 · Cited by 108
Prevalent Vertebral Fractures in Black Women and White Women
Cauley, J. A., Palermo, L., Vogt, M. T., Ensrud, K. E., Ewing, S. K., Hochberg, M. C., Nevitt, M. C., & Black, D. M. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080411 · Cited by 113
Self-citationKim, S. C., Kim, D. H., Mogun, H., Eddings, W., Polinski, J. M., Franklin, J. M., & Solomon, D. H. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2832 · Cited by 105
“001) in the Health Outcomes and Reduced Incidence with Zoledronic acid Once Yearly–Pivotal Fracture Trial (HORIZON-PFT) trial,((8)) but the risk does not appear to be increased in”
BackgroundReconstruction of Defects Caused by Bisphosphonate-Induced Osteonecrosis of the Jaws
Marx, R. E. (2009) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2008.12.007 · Cited by 108
Rubin, K. H., Rothmann, M. J., Holmberg, T., Høiberg, M., Möller, S., Barkmann, R., Glüer, C.-C., Hermann, A. P., Bech, M., Gram, J., et al. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4326-3 · Cited by 104
Reduction in the Risk of Clinical Fractures After a Single Dose of Zoledronic Acid 5 Milligrams
Reid, I. R., Black, D. M., Eastell, R., Bucci-Rechtweg, C. M., Su, G., Hue, T. F., Mesenbrink, P. G., Lyles, K. W., & Boonen, S. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2868 · Cited by 105
“New morphometric vertebral fractures were only assessed in HORIZON-PFT and were reduced by 68% by zoledronic acid in those receiving a single infusion (zoledronic acid: 7 fractures in 154 subjects; placebo: 14 in 98, P .004) and by 69% in those having 3 infusions (zoledronic acid: 95 fractures in 3028 subjects; placeb…”
BackgroundMethodInfluentialSelf-citationBody, J. J., Bergmann, P., Boonen, S., Boutsen, Y., Devogelaer, J.-P., Goemaere, S., Kaufman, J., Rozenberg, S., & Reginster, J.-Y. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1223-4 · Cited by 116
“001) [86].”
Self-citationOsteoporosis as a Risk Factor for Distal Radial Fractures: A Case-Control Study
Øyen, J., Brudvik, C. E., Gjesdal, C. G., Tell, G. S., Lie, S. A., & Hove, L. M. (2011) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.j.00303 · Cited by 119
Gasser, J. A., Ingold, P., Venturiere, A., Shen, V., & Green, J. R. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.071207 · Cited by 107
Shapiro, C. L., Halabi, S., Hárs, V., Archer, L. E., Weckstein, D. J., Kirshner, J. J., Sikov, W. M., Winer, E. P., Burstein, H. J., Hudis, C. A., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2010.11.024 · Cited by 102
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis
Russell, R. G. G. (2010) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s8054 · Cited by 118
Romosozumab for the treatment of osteoporosis
Bandeira, L., Lewiecki, E. M., & Bilezikian, J. P. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1280455 · Cited by 101
Postmenopausal osteoporosis: Assessment and management
Rizzoli, R. (2018) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2018.09.005 · Cited by 139
Safety of Long-Term Bisphosphonate Therapy for the Management of Osteoporosis
Lewiecki, E. M. (2011) · Drugs · doi:10.2165/11585470-000000000-00000 · Cited by 111
“Since these drugs are administered by injection and do not accumulate in the gastrointestinal tract, they have not been associated with a increase in gastrointestinal events.([11,12]) 2.”
BackgroundMethodInfluentialJansen, J. P., Bergman, G., Huels, J., & Olson, M. S. (2010) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2010.06.001 · Cited by 113
“Relative Risk zoledronic acid [8]”
Rozental, T. D., Vazquez, M. A., Chacko, A. T., Ayogu, N., & Bouxsein, M. (2009) · The Journal Of Hand Surgery · doi:10.1016/j.jhsa.2008.12.011 · Cited by 104
Cooper, M. S., Palmer, A. J., & Seibel, M. J. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1802-z · Cited by 111
Calcium supplementation in osteoporosis: useful or harmful?
Chiodini, I., & Bolland, M. J. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0113 · Cited by 110
Efficacy and safety of monthly ibandronate in men with low bone density
ORWOLL, E. S., Binkley, N., Lewiecki, E. M., Gruntmanis, U., Fries, M. A., & Dašić, G. (2010) · Bone · doi:10.1016/j.bone.2009.12.034 · Cited by 109
“In particular, the bisphosphonates have demonstrated efficacy in reducing fracture risk in women with postmenopausal osteoporosis [10–13].”
BackgroundEfficacy, effectiveness and side effects of medications used to prevent fractures
Reid, I. R. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12339 · Cited by 105
“Intravenous amino-bisphosphonates are potentially nephrotoxic, though this was not a significant problem during the Phase III trials of zoledronate [40].”
Self-citationMicroRNAs in Osteoclastogenesis and Function: Potential Therapeutic Targets for Osteoporosis
Xiao, J., Chen, X., & Yu, X. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030349 · Cited by 104
“There exist several potential adverse clinical events concomitant with the medication of bisphosphonates, including osteonecrosis of the jaw [74], atrial fibrillation [75], acute inflammatory response [75], and oversuppression of bone turnover [76].”
BackgroundBisphosphonates—much more than only drugs for bone diseases
Kuźnik, A., Październiok-Holewa, A., Jewuła, P., & Kuźnik, N. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172773 · Cited by 114
Skeletal Effects of Interventions in Mild Primary Hyperparathyroidism: A Meta-Analysis
Sankaran, S., Gamble, G. D., Bolland, M. J., Reid, I. R., & Grey, A. B. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2384 · Cited by 97
Self-citationSafety of Bisphosphonates in the Treatment of Osteoporosis
Recker, R. R., Lewiecki, E. M., Miller, P. D., & Reiffel, J. A. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.12.004 · Cited by 106
Puhaindran, M. E., Farooki, A., Steensma, M. R., Hameed, M., Healey, J. H., & Boland, P. J. (2011) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.j.01199 · Cited by 102
Gallacher, S., & Dixon, T. (2010) · Calcified Tissue International · doi:10.1007/s00223-010-9420-x · Cited by 101
“Treatment with a once-yearly infusion of zoledronate (5 mg) significantly reduces the risk of vertebral, nonvertebral, hip, and wrist fracture in postmenopausal women with osteoporosis [ 36 ].”
BackgroundThe Treatment Gap in Osteoporosis
Ayub, N., Faraj, M., Ghatan, S., Reijers, J. A. A., Napoli, N., & Oei, L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10133002 · Cited by 98
Metadata
- Authors
- Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., Mautalen, C., Mesenbrink, P., Hu, H., Caminis, J., Tong, K., Rosario-Jansen, T., Krasnow, J., Hue, T. F., Sellmeyer, D., Eriksen, E. F., & Cummings, S. R.
- Affiliations
- University of California, San Francisco (US)
- Lyon 1 Université (FR)
- University of Sheffield (GB)
- University of Auckland (NZ)
- KU Leuven (BE)
- University of Pittsburgh (US)
- Helen Hayes Hospital (US)
- Semmelweis University (HU)
- Chinese University of Hong Kong (HK)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-05-03
- Volume
- 356
- Issue
- 18
- Pages
- 1809-1822
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1993035292
- Cited by
- 2,986
- References
- 34
- Citations by year
- 2026: 90 · 2025: 120 · 2024: 107 · 2023: 96 · 2022: 114 · 2021: 140 · 2020: 127 · 2019: 124 · 2018: 127 · 2017: 121 · 2016: 150 · 2015: 154 · 2014: 154 · 2013: 194 · 2012: 174
- FWCI
- 258.58
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- ResearchSpace (University of Auckland) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR000005)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- zoledronic acid, postmenopausal osteoporosis, bisphosphonates, fracture risk reduction, vertebral fractures, hip fracture, bone mineral density, bone turnover markers, atrial fibrillation, renal function
- MeSH terms
- Zoledronic Acid, Aged, Aged, 80 and over, Atrial Fibrillation, Diphosphonates, Double-Blind Method, Drug Administration Schedule, Female, Hip Fractures, Humans, Imidazoles, Infusions, Intravenous, Risk, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Incidence, Spinal Fractures, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.